Skip to main content
. 2020 Apr 1;13(4):100766. doi: 10.1016/j.tranon.2020.100766

Table 2.

GZD824 inhibits proliferation in Ba/F3 cells expressing FLT3 and mutant isoforms

IC50 (nM) Midostaurin
Gilteritinib (ASP2215) Quizartinib
GZD824
(PKC412) (AC220)
BaF3-Tel-FLT3-ITD 21.8 5 2 1.8
BaF3-tel-FLT3 14.4 57 3.1 2.3
BaF3-FLT3-MOLM-ITD 4 3.1 0.8 0.8
BaF3-FLT3-ITD-D835N 6.5 3.5 1.6 3
BaF3-FLT3-ITD-Y842H 1.3 1.5 5.3 3.2
BaF3-FLT3-ITD-Y842R 1.6 2.1 7.2 4.2
BaF3-tel-FLT3-D835Y 1 2.5 2.4 5.7
BaF3-FLT3-ITD-D835G 5.8 3.8 4.3 7.8
BaF3-FLT3-ITD-D835A 5.8 1.9 3.1 9.3
BaF3-FLT3-ITD-N676D 62.4 9.6 8.3 7.2
BaF3-FLT3-ITD-F691I 41.9 32.8 95 1.4
BaF3-FLT3-ITD-G697R 116.3 307 22.8 9.4
BaF3-FLT3-D835H 6.6 3.4 4 17.6
BaF3-FLT3-D835V 3.3 3.7 40.2 34.7
BaF3-FLT3-ITD-D835Y 6.4 2.9 35.5 35.7
BaF3-FLT3-ITD-D835V 3.8 1.6 125.6 49.9
BaF3-FLT3-ITD-D835I 3.5 1.6 182.8 58.5
BaF3-tel-FLT3-R834Q 63.1 252.1 >1000 76.2
BaF3-tel-FLT3-K663Q 102.1 389.7 >1000 853.3

The anti-proliferative activities of compounds evaluated with a CCK-8 assay.